Global CDMO Power mAbxience operates GMP-approved multi-product facilities across Europe and South America, offers end-to-end CDMO services, and maintains a broad B2B footprint with many markets and partners. This signals strong capacity for contract development and manufacturing, especially for biosimilars and oncology products, with potential for global supply partnerships.

Oncology Biosimilars Active expansion into oncology biosimilars through collaboration with Teva highlights a strategic focus on cancer products, creating opportunities for co-development, manufacturing partnerships, and supply arrangements in oncology portfolios.

Backed for Growth Ownership by major pharmaceutical groups provides strategic backing for scale and global expansion, enabling long-term manufacturing partnerships, access to capital, and integration into a broader global supply network.

Global Market Reach Extensive worldwide market reach and a robust partner network offer pathways to co-develop or co-commercialize products in diverse regions, leveraging regulatory and distribution capabilities to reach underserved markets.

Tech-Driven CDMO Adoption of advanced bioprocess automation and a leadership transition indicate a modernization trajectory and readiness to engage in digital collaboration, process optimization, and high-efficiency development and manufacturing programs for partner clients.